We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Formology Lab of Chatsworth, Calif., earned an FDA warning letter for failing to verify the identity of each component of a drug product, having no written procedures for process or production control as well as not having established an adequate quality control unit, among other serious lapses.
The FDA outlined its current thinking for drug sponsors on assessing gastric pH-dependent drug-drug interactions (DDI) in a final guidance released Monday.